Onsdag 30 Oktober | 09:26:12 Europe / Stockholm

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Prenumeration

Kalender

Tid*
2025-02-13 08:30 Bokslutskommuniké 2024
2024-11-08 08:30 Kvartalsrapport 2024-Q3
2024-08-22 - Kvartalsrapport 2024-Q2
2024-05-16 - X-dag ordinarie utdelning SENZA 0.00 SEK
2024-05-15 - Årsstämma
2024-05-15 - Kvartalsrapport 2024-Q1
2024-02-14 - Bokslutskommuniké 2023
2023-08-24 - Kvartalsrapport 2023-Q2
2023-05-05 - X-dag ordinarie utdelning SENZA 0.00 SEK
2023-05-04 - Årsstämma
2023-02-16 - Bokslutskommuniké 2022
2022-08-18 - Kvartalsrapport 2022-Q2
2022-05-06 - X-dag ordinarie utdelning SENZA 0.00 SEK
2022-05-05 - Årsstämma
2022-02-11 - Bokslutskommuniké 2021
2021-08-19 - Kvartalsrapport 2021-Q2
2021-05-06 - X-dag ordinarie utdelning SENZA 0.00 SEK
2021-05-05 - Årsstämma
2021-02-18 - Bokslutskommuniké 2020
2020-08-20 - Kvartalsrapport 2020-Q2
2020-05-11 - X-dag ordinarie utdelning SENZA 0.00 SEK
2020-05-08 - Årsstämma
2020-02-13 - Bokslutskommuniké 2019
2019-12-18 - Extra Bolagsstämma 2019
2019-08-22 - Kvartalsrapport 2019-Q2
2019-05-16 - X-dag ordinarie utdelning SENZA 0.00 SEK
2019-05-15 - Årsstämma
2019-02-14 - Bokslutskommuniké 2018
2018-08-22 - Kvartalsrapport 2018-Q2
2018-05-09 - X-dag ordinarie utdelning SENZA 0.00 SEK
2018-05-08 - Årsstämma
2018-02-14 - Bokslutskommuniké 2017

Beskrivning

LandSverige
ListaFirst North Stockholm
SektorHälsovård
IndustriBioteknik
Senzagen är verksamt inom medicinteknik. Bolaget utvecklar och genomför genomiska in vitro-tester, vilket innebär att olika kemikaliers toxikologiska förmåga inte testas på djur utan istället i provrör. Bolaget har utvecklat en teknologisk plattform som används för att studera substansers påverkan producerat av aktörer inom läkemedel, kosmetika- och kemikalieindustrin. Forskning och utveckling sker från huvudkontoret i Lund.
2023-11-08 09:01:00

SenzaGen develops and sells non-animal chemical tests and is now one of Sweden's fastest-growing technology companies according to Deloitte's annual ranking, Sweden Technology Fast 50. Over the past four years, SenzaGen has had an average growth rate of 1433 percent. SenzaGen ranked 18th out of 50 companies on the list.

"Being ranked as one of Sweden's fastest-growing technology companies is evidence that our business model has yielded fantastic results and that what we do is perfectly timed. We are incredibly proud of how our innovations contribute both ethically and scientifically when we assist companies in transitioning away from animal testing while providing them with test results directly applicable to humans. As CEO, I feel immense pride in our team, which has delivered these results. They form the basis for this award and truly strengthen us on our continued growth journey," says Peter Nählstedt, President and CEO of SenzaGen.

The ranking in Sweden Technology Fast 50 is based on the growth in net revenue over the past four years.

"It feels fantastic to have been able to highlight Swedish entrepreneurship in the tech industry for 20 years through Sweden Technology Fast 50. This year's companies not only reflect Sweden's leading position in innovation but also some of the shifts we have seen in society in recent years, not least within GreenTech, where technical solutions are used to address climate change, and MedTech, where technology is used to strengthen healthcare. We are happy to celebrate the companies' success and look forward to following their journey, says Ester Sundström, partner at Deloitte and responsible for the Deloitte Sweden Technology Fast 50.

The 2023 ranking is being presented at an event at Nasdaq in Stockholm on November 9. Learn more about the award, its background, and more detailed criteria at www.deloitte.se/fast50.

SenzaGen leverages its extensive expertise in various technology areas, including genomics, machine learning, and human tissue models, to develop better and more ethical testing methods that can replace animal experiments in toxicological evaluations of chemicals.